Given the proven role of the renin-angiotensin system in the development of diabetic macular edema, the availability of low-cost oral systemic drugs, and relatively few complications to block this system, the use of angiotensin receptor blockers (ARBs) such as Losartan simultaneously with intravitreal injection of Anti-VEGF compounds, including Bevacizumab, which is one of the most effective therapies currently available, may improve the clinical response to these drugs and reduce the frequency of injections. Here, VEGFA is linked to diabetic macular edema.